Mixed dementia. A review of the evidence
Fuente:
Redalyc
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Associação Neurologia Cognitiva e do Comportamento
2017
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1876424560769761280 |
|---|---|
| author | Nilton Custodio |
| author_facet | Nilton Custodio |
| contents | Mixed dementia. A review of the evidence Nilton Custodio Rosa Montesinos David Lira Eder Herrera-Pérez Yadira Bardales Lucía Valeriano-Lorenzo Medicina Mixed dementia vascular dementia Alzheimer’s disease cerebrovascular disease Mixed dementia is the coexistence of Alzheimer’s disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer’s dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer’s dementia and VD. The non- pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD. 2017 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339554592005 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.11 |
| format | Artículo científico |
| id | redalyc_339554592005 |
| institution | Redalyc |
| language | en |
| publishDate | 2017 |
| publisher | Associação Neurologia Cognitiva e do Comportamento |
| spellingShingle | Mixed dementia. A review of the evidence Nilton Custodio Medicina Mixed dementia vascular dementia Alzheimer’s disease cerebrovascular disease Mixed dementia. A review of the evidence Nilton Custodio Rosa Montesinos David Lira Eder Herrera-Pérez Yadira Bardales Lucía Valeriano-Lorenzo Medicina Mixed dementia vascular dementia Alzheimer’s disease cerebrovascular disease Mixed dementia is the coexistence of Alzheimer’s disease and cerebrovascular disease (CVD) in the same demented patient. Currently, its diagnosis and treatment remains a challenge for practitioners. To provide an overview of the epidemiology, pathogenesis, natural history, diagnosis, and therapy of Mixed Vascular-Alzheimer Dementia (MVAD). The literature was reviewed for articles published between 1990-2016 by using the keywords linked to MVAD. Neuropathological studies indicate that MVAD is a very common pathological finding in the elderly with a prevalence about of 22%. The distinction between Alzheimer’s dementia and vascular dementia (VD) is complex because their clinical presentation can overlap. There are international criteria for the MVAD diagnosis. The pharmacologic therapy shows modest clinical benefits that are similar among all drugs used in patients with Alzheimer’s dementia and VD. The non- pharmacologic therapy includes the rigorous management of cardiovascular risk factors (especially hypertension) and the promotion of a healthy diet. The diagnosis and treatment of MVAD cannot be improved without further studies. Currently available medications provide only modest clinical benefits once a patient has developed MVAD. In subjects at risk, the antihypertensive therapy and healthy diet should be recommend for preventing or slowing the progression of MVAD. 2017 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339554592005 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.11 |
| title | Mixed dementia. A review of the evidence |
| topic | Medicina Mixed dementia vascular dementia Alzheimer’s disease cerebrovascular disease |
| url | https://www.redalyc.org/articulo.oa?id=339554592005 |